X

Trial Profile

A non-randomised phase 2 pilot study of accelerated BEP [bleomycin etoposide platinum] chemotherapy for intermediate and high risk metastatic germ cell tumours.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bleomycin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Pegfilgrastim (Primary)
Indications Germ cell cancer; Peritoneal cancer; Testicular cancer
Focus Adverse reactions; Therapeutic Use
Acronyms Accelerated-BEP

Most Recent Events

06 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
03 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
03 Feb 2010 Planned end date changed from 31 Dec 2009 to 18 Jan 2010 as reported by United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com